Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523868 · ClinicalTrials.gov registry record · NA
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
A NA study of Cancer Diagnosis, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 1
- Study location
NCT06523868: Recruiting NA study of Cancer Diagnosis, sponsored by Dana-Farber Cancer Institute.
NCT06523868 is a NA study of Cancer Diagnosis that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,500 participants, below the 6,544-participant average among 4 other Cancer Diagnosis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06523868, a NA study of Cancer Diagnosis, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Primary Outcome
Positive predictive value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results.
Conditions Studied
Interventions
- OTHER GRAIL Galleri
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2028-09-30 |
| Phase | NA |
What NCT06523868 shows while recruiting
NCT06523868 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 6,544-participant average among 4 other Cancer Diagnosis trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Cancer Diagnosis appearing as the primary indexed condition, and to 1 intervention - of which GRAIL Galleri is the first listed.
NCT06523868 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06523868 about?
NCT06523868 is a clinical study titled "Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study". The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The nam...
What is the current status of trial NCT06523868?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2025-03-31. Estimated completion is 2028-09-30.
What conditions does trial NCT06523868 study?
This clinical trial studies the following conditions: Cancer Diagnosis.
What interventions are being tested in trial NCT06523868?
The interventions under investigation include: GRAIL Galleri (OTHER).
Who is sponsoring clinical trial NCT06523868?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06523868 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Diagnosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRISM for Depression and Anxiety in Young Adults With Cancer
ACTIVE NOT RECRUITING · NA
-
Building Resiliency Among Caregivers of Curvivors and Metavivors
COMPLETED · NA
-
Avera Cancer Sequencing and Analytics Protocol (ASAP)
RECRUITING
-
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI